Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Trip.com Group Ltd — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.91 (market cap $4.49B), while Trip.com Group Ltd trades at $41.57 (market cap $25.65B). The key difference: Trip.com Group Ltd is far larger — about 5.7× ACADIA Pharmaceuticals Inc.'s market cap, and Trip.com Group Ltd pays a 0.57% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | TCOM | |
|---|---|---|
Market Cap | $4.49B | $25.65B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $78.96 |
52-Week Low | $20.06 | $39.84 |
Enterprise Value | $3.69B | $18.35B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Trip.com Group (TCOM) trades at $40.81, down 0.46% on the day, near its 52-week low. The stock shows bearish technical signals with oversold RSI readings. Fundamentally, TCOM reported Q1 2026 revenue growth of 17% year-over-year but missed EPS estimates, with Q2 revenue guidance of 3%-8% growth disappointing investors. The company maintains strong profitability with a 48.65% net margin and attractive valuation multiples, including a P/E of 6.16. Recent news highlights regulatory scrutiny and a significant stock selloff following earnings.
The outlook for TCOM is mixed. Strong cash flow, dominant market position in Chinese travel, and low valuations support upside potential toward the $56.72 analyst target. However, near-term risks include regulatory investigations, margin pressure from cost growth, and bearish technical trends. Investors should weigh solid fundamentals against heightened sentiment risks and guidance concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
